FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971082993> ?p ?o ?g. }

• W2971082993 endingPage "403" @default.
• W2971082993 startingPage "394" @default.
• W2971082993 abstract "Summary Ibrutinib‐related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly outside of trials. We report on 80 patients [previously treated, n = 67 (84%), treatment‐naïve, n = 13 (16%)] with WM, evaluated consecutively at Mayo Clinic, who received ibrutinib off‐study after its approval in 2015 for WM. Overall response rate (ORR) was 91%; major‐response rate (MRR) was 78%. The median time to first response and best response was 2·9 [95% confidence interval (CI): 2–4] and 5·7 (95% CI: 4–12) months, respectively. The median follow‐up was 19 (95% CI: 14–21) months; 18‐month progression‐free survival (PFS) was 82%. The median time on therapy was 12·5 (95% CI: 9·3–16·7) months, and the median duration‐of‐response was 32 (range: 23–32) months. Twenty‐five patients (31%) had discontinued therapy at last follow‐up (68% due to treatment‐related toxicities) and 18% of patients required dose reduction. Fatigue (12%) and atrial‐fibrillation (11%) were common non‐haematological toxicities. IgM rebound occurred in 36% of patients who abruptly discontinued ibrutinib. Following ibrutinib discontinuation, 84% of patients received subsequent treatment, achieving an ORR of 57% and MRR of 50%. The median PFS from commencement of subsequent salvage therapy was 18 months. Ibrutinib therapy, outside of clinical trials, is effective in WM, but is associated with toxicities and challenges, including IgM rebound and a high drug discontinuation rate for reasons other than disease progression." @default.
• W2971082993 created "2019-09-05" @default.
• W2971082993 creator A5002248011 @default.
• W2971082993 creator A5002296964 @default.
• W2971082993 creator A5004152557 @default.
• W2971082993 creator A5009747339 @default.
• W2971082993 creator A5010727520 @default.
• W2971082993 creator A5014972717 @default.
• W2971082993 creator A5016853434 @default.
• W2971082993 creator A5023193953 @default.
• W2971082993 creator A5024819739 @default.
• W2971082993 creator A5025688165 @default.
• W2971082993 creator A5026574827 @default.
• W2971082993 creator A5029802364 @default.
• W2971082993 creator A5031537463 @default.
• W2971082993 creator A5033220547 @default.
• W2971082993 creator A5037472340 @default.
• W2971082993 creator A5056260546 @default.
• W2971082993 creator A5057465226 @default.
• W2971082993 creator A5058688409 @default.
• W2971082993 creator A5059729547 @default.
• W2971082993 creator A5068637846 @default.
• W2971082993 creator A5071201232 @default.
• W2971082993 creator A5072502164 @default.
• W2971082993 creator A5076071872 @default.
• W2971082993 creator A5076611748 @default.
• W2971082993 creator A5077686486 @default.
• W2971082993 date "2019-08-29" @default.
• W2971082993 modified "2023-10-07" @default.
• W2971082993 title "Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes" @default.
• W2971082993 cites W1790337787 @default.
• W2971082993 cites W1972632013 @default.
• W2971082993 cites W2003734726 @default.
• W2971082993 cites W2007851220 @default.
• W2971082993 cites W2083373405 @default.
• W2971082993 cites W2091319225 @default.
• W2971082993 cites W2108120512 @default.
• W2971082993 cites W2116382435 @default.
• W2971082993 cites W2128490833 @default.
• W2971082993 cites W2133192145 @default.
• W2971082993 cites W2140380015 @default.
• W2971082993 cites W2150724746 @default.
• W2971082993 cites W2299610149 @default.
• W2971082993 cites W2529668746 @default.
• W2971082993 cites W2560708148 @default.
• W2971082993 cites W2570226453 @default.
• W2971082993 cites W2582201808 @default.
• W2971082993 cites W2778168818 @default.
• W2971082993 cites W2789889288 @default.
• W2971082993 cites W2791441078 @default.
• W2971082993 cites W2796163957 @default.
• W2971082993 cites W2805689516 @default.
• W2971082993 cites W2890429531 @default.
• W2971082993 cites W2891934670 @default.
• W2971082993 cites W2892094854 @default.
• W2971082993 cites W2941780980 @default.
• W2971082993 cites W2592549712 @default.
• W2971082993 doi "https://doi.org/10.1111/bjh.16168" @default.
• W2971082993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31468508" @default.
• W2971082993 hasPublicationYear "2019" @default.
• W2971082993 type Work @default.
• W2971082993 sameAs 2971082993 @default.
• W2971082993 citedByCount "36" @default.
• W2971082993 countsByYear W29710829932020 @default.
• W2971082993 countsByYear W29710829932021 @default.
• W2971082993 countsByYear W29710829932022 @default.
• W2971082993 countsByYear W29710829932023 @default.
• W2971082993 crossrefType "journal-article" @default.
• W2971082993 hasAuthorship W2971082993A5002248011 @default.
• W2971082993 hasAuthorship W2971082993A5002296964 @default.
• W2971082993 hasAuthorship W2971082993A5004152557 @default.
• W2971082993 hasAuthorship W2971082993A5009747339 @default.
• W2971082993 hasAuthorship W2971082993A5010727520 @default.
• W2971082993 hasAuthorship W2971082993A5014972717 @default.
• W2971082993 hasAuthorship W2971082993A5016853434 @default.
• W2971082993 hasAuthorship W2971082993A5023193953 @default.
• W2971082993 hasAuthorship W2971082993A5024819739 @default.
• W2971082993 hasAuthorship W2971082993A5025688165 @default.
• W2971082993 hasAuthorship W2971082993A5026574827 @default.
• W2971082993 hasAuthorship W2971082993A5029802364 @default.
• W2971082993 hasAuthorship W2971082993A5031537463 @default.
• W2971082993 hasAuthorship W2971082993A5033220547 @default.
• W2971082993 hasAuthorship W2971082993A5037472340 @default.
• W2971082993 hasAuthorship W2971082993A5056260546 @default.
• W2971082993 hasAuthorship W2971082993A5057465226 @default.
• W2971082993 hasAuthorship W2971082993A5058688409 @default.
• W2971082993 hasAuthorship W2971082993A5059729547 @default.
• W2971082993 hasAuthorship W2971082993A5068637846 @default.
• W2971082993 hasAuthorship W2971082993A5071201232 @default.
• W2971082993 hasAuthorship W2971082993A5072502164 @default.
• W2971082993 hasAuthorship W2971082993A5076071872 @default.
• W2971082993 hasAuthorship W2971082993A5076611748 @default.
• W2971082993 hasAuthorship W2971082993A5077686486 @default.
• W2971082993 hasBestOaLocation W29710829931 @default.
• W2971082993 hasConcept C126322002 @default.
• W2971082993 hasConcept C141071460 @default.
• W2971082993 hasConcept C2777938653 @default.
• W2971082993 hasConcept C2778461978 @default.

• next